Both linked to improvements in visual acuity; only triamcinolone tied to sustained improvement in CMT
For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients.
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer
Adding bevacizumab to chemotherapy for the postsurgical treatment of triple-negative breast cancer does not significantly improve invasive disease-free survival compared with chemotherapy alone.
ESMO 2021, News
There was no improvement in overall survival with bevacizumab.
Researchers conducted a secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2mg), bevacizumab (1.25mg), or ranibizumab (0.3mg).
Drugs in the Pipeline
Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.
The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.
Avastin (bevacizumab) and Lucentis (ranibizumab) have similar effects on visual acuity in age-related macular degeneration (AMD).
The addition of bevacizumab to combination chemotherapy for the treatment of stage IV colorectal cancer increases overall survival, particularly for patients receiving irinotecan-based chemotherapy regimens, but is associated with increased rates of strokes and gastrointestinal (GI) perforations, according to a study published online January 17 in the Journal of Clinical Oncology.